Sumitomo Pharmaceuticals Licenses DACH Platinum Derivative to Aronex Pharmaceuticals, Inc.
Sumitomo Pharmaceuticals Co., Ltd. and Aronex Pharmaceuticals, Inc. (Texas, USA) reached an agreement on December 12, 2000, in which Sumitomo Pharmaceuticals gives Aronex Pharmaceuticals rights to its patent on DACH platinum derivatives.
Aronex Pharmaceuticals, Inc., established as Argus Pharmaceuticals, Inc. in 1986 in Texas, USA, is a biopharmaceutical company that develops and commercializes proprietary medicines to treat cancer and infectious diseases.
Under the terms of the License Agreement, Aronex Pharmaceuticals has been granted rights to develop and sell its anti-tumor drug, Aroplatin, in the United States. Sumitomo Pharmaceuticals will receive an up-front payment, subsequent milestones based on regulatory filings and approval, and royalties on the US sales of Aroplatin.
Sumitomo Pharmaceuticals is developing its own alkyl derivative of a platinum compound, SM-11355, for the treatment of cancer. Sumitomo Pharmaceuticals filed a patent covering SM-11355 in the United States, which was issued after resolving interference proceedings with the Aronex patent at the USPTO. This agreement to license the patent is the result of negotiations with Aronex Pharmaceuticals.
Additionally, the issuance of the US patent to Sumitomo Pharmaceuticals will enable the firm to continue its own development of SM-11355 for the United States market.